| |
Tuesday, April 30, 2024 | 2pm ET / 11am PT Liquid biopsies have shown tremendous progress for the early detection of cancer and for treatment monitoring, but still have limitations. The inclusion of protein glycosylation can help. Join us to learn more about the latest solutions for leveraging AI and machine learning to accelerate data processing, overcome current barriers, and provide crucial information. Register now.
|
|
Today’s Big NewsApr 26, 2024 |
| By Max Bayer Bristol Myers Squibb is closing a 256,000-square-foot research facility in Redwood City, CA as part of the company's larger restructuring. Scientists at the site homed in on studying the tumor microenvironment. |
|
|
|
By Zoey Becker As Humira continues its sales free fall, newer Skyrizi is proving a worthy successor with nearly matching sales ahead of an upcoming FDA decision in ulcerative colitis. |
By Conor Hale According to Invitae the transaction covers “substantially all of the company’s assets”—though the testing giant Labcorp described them as “select.” |
By Nick Paul Taylor A $4.9 billion hole has appeared in Gilead’s pipeline. After years of setbacks, the big biotech dealt a final blow to its anti-CD47 monoclonal antibody magrolimab Thursday by removing the remaining solid tumor trials from its pipeline. |
|
Tuesday, May 7, 2024 | 11 ET / 8 am PT This webinar dives into challenges and strategies in commercializing cell and gene therapies. Experts explore process standardization, treatment tracking tech, network channel strategy, and scaling for commercial success in this promising but complex field. Register now.
|
|
By Kevin Dunleavy Ten years after dipping its toe into the gene therapy pool in a licensing deal with Spark Therapeutics, Pfizer has gained an FDA approval for the acquired treatment. The U.S. regulator has endorsed Beqvez for adults with the bleeding disorder hemophilia B. It becomes the first FDA-approved gene therapy for Pfizer, which will charge $3.5 million for the single-dose drug. |
By Conor Hale The Inceptiv implant for chronic pain aims to keep pace with the body’s nerve activity as the patient goes through their daily life. |
By Angus Liu After a negative phase 3 readout, Gilead Sciences is taking a $2.4 billion impairment charge on the antibody-drug conjugate Trodelvy. With a busy year ahead across therapeutic areas, CEO Dan O'Day emphasized a "time of focused execution." |
By Max Bayer,Gabrielle Masson,Andrea Park Last year was a difficult one for ex-Stanford president Marc Tessier-Lavigne, Ph.D. An investigation into his prior research from the campus’ student newspaper ultimately led to his resignation. But the once-chief scientific officer of Genentech is now back in biotech. |
By Zoey Becker The company opted not to renew its Biotechnology Innovation Organization (BIO) membership for its next fiscal year. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce Pharma Senior Editor Eric Sagonowsky and Senior Writer Kevin Dunleavy are diving into our annual top pharma companies by revenue special report. |
|
|---|
|
|
|
Wednesday, May 13, 2024 | 10 ET / 7 am PT This webinar unveils AI's transformative role in life sciences, presented by industry experts. Learn how AI process automation expedites drug development, ensures regulatory compliance, enhances communication, and boosts collaboration. Register now.
|
|
| WhitepaperDiscover the secrets behind successful patient engagement Sponsored by: ProofPilot |
| WhitepaperAntibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| eBookUnlock the future of monoclonal antibody (mAb) manufacturing with a complete guide to enhancing productivity and quality for exceptional outcomes. Sponsored by: Thermo Fisher Scientific |
| WhitepaperThis paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperChoosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
